Comparison of initial efficacy and long-term follow-up of heparin-coated Jostent with conventional NIR stent

Related Experiment Videos

Ender Semiz1, Cengiz Ermiş, Selim Yalçinkaya

  • 1Department of Cardiology, Pamukkale University Medical School, Denizli, Turkey.

Japanese Heart Journal
|January 9, 2004
PubMed

Insights

Heparin-coated Jostents showed no significant benefit over uncoated NIR stents in preventing thrombosis or restenosis. Clinical outcomes and angina classification were similar between the two stent types in this comparative study.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials in Medicine

Background:

  • Heparin-coated stents are used to reduce thrombotic complications after coronary implantation.
  • Conflicting data exists regarding the efficacy of heparin-coated stents compared to uncoated stents, particularly concerning acute complications and long-term outcomes.

Purpose of the Study:

  • To compare the angiographic and clinical outcomes of heparin-coated Jostents versus uncoated NIR stents.
  • To evaluate differences in acute/subacute thrombosis, major adverse cardiac events, restenosis rates, and functional angina classification.

Main Methods:

  • A comparative study involving 426 patients undergoing coronary stent implantation.
  • Patients received either heparin-coated Jostent (n=230) or uncoated NIR stent (n=196).
  • Primary endpoints included thrombosis, urgent CABG, AMI, or death; secondary endpoints were restenosis and angina classification at various follow-up intervals.

Main Results:

  • No significant differences were observed in angiographic success, procedural success, acute thrombosis, or subacute thrombosis between the Jostent and NIR stent groups.
  • Major adverse cardiac event rates were similar. Angiographic restenosis rates were 17% for Jostent and 16% for NIR stents.
  • Combined clinical and angiographic restenosis rates and functional angina classifications at 1, 6, and 12 months showed no significant differences between groups.

Conclusions:

  • Heparin-coated Jostent implantation offers no significant advantage over uncoated NIR stent implantation regarding initial efficacy, thrombosis, or 6-month restenosis rates.
  • Long-term clinical outcomes up to 12 months were also comparable between the heparin-coated and uncoated stent groups.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...